Abbott Agrees to 670M Formula Settlement
Abbott reached a 670 million dollar settlement to partially resolve litigation over specialty infant formulas linked to a dangerous bowel disease. The deal drops appeals in a major 2024 judgment while leaving thousands of other claims pending.
Xurve View
Insights:
Xurve View
ABBOTT LABORATORIES will pay $670 million to resolve litigation over specialty infant formulas tied to a dangerous bowel disease. The deal covers about 2,000 claimants and halts the company's appeal of a $495 million verdict from 2024. The settlement limits legal exposure in the United States, where thousands of similar cases remain pending across state and federal courts.
